

Review/Meta-analysis

Cite this article: Catthoor K, Detraux J, De Hert M (2025). The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review. *European Psychiatry*, **68**(1), e36, 1–15 <https://doi.org/10.1192/j.eurpsy.2025.18>

Received: 14 September 2024

Revised: 31 January 2025

Accepted: 02 February 2025

Keywords:

antidepressant; antiemetic; antiepileptic; dystonia; mood stabilizer

Corresponding author:

Johan Detraux;

Email: johan.detraux@upckuleuven.be

The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review

Kirsten Catthoor^{1,2,3} , Johan Detraux^{4,5}  and Marc De Hert^{4,6,7} 

¹Ziekenhuis Netwerk Antwerpen (ZNA), Antwerp, Belgium; ²Flemish Psychiatric Association, Kortenberg, Belgium;

³Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium; ⁴University

Psychiatric Center KU Leuven, Kortenberg, Belgium; ⁵Research Group Psychiatry, KU Leuven, Leuven, Belgium;

⁶Department of Neurosciences, Research Group Psychiatry, Center for Clinical Psychiatry, KU Leuven, Leuven, Belgium and ⁷Antwerp Health Law and Ethics Chair, AHLEC University Antwerpen, Antwerp, Belgium

Abstract

Background. Medication-induced dystonia (MID) is a movement disorder (MD), characterized by involuntary sustained or intermittent muscle contractions, causing abnormal, often repetitive, movements, postures, or both. Although MID is commonly associated with the use of antipsychotics, it also occurs with many other medications widely used in clinical practice.

Methods. A systematic literature search (from inception to November 2023), using the PubMed and Embase databases, was conducted without language restriction for articles reporting on MID in people without pre-existing MDs, and this for all potentially relevant non-antipsychotic medications. A narrative synthesis of the available evidence was undertaken.

Results. MID is common (1 to 10%) with certain antiemetics. Selective serotonin reuptake inhibitors and the antiepileptics valproate, carbamazepine, and lamotrigine are rarely (0.01 to 0.1%) or very rarely (<0.01%) associated with MID. All other medications are very rarely (<0.01%) associated with MID or have a risk that cannot be precisely estimated. The actual rate of dystonic reactions with most non-antipsychotic agents remains unknown, owing to misdiagnosis and underreporting in the scientific literature. In general, MID seems to occur more often in children and adolescents, even with a single low dose, and with polymedication. In most cases, MID is acute in onset (occurring within hours to days) and involves the head and neck.

Conclusions. Although MID is most common with dopamine receptor-blocking antiemetics, many other medications may also produce dystonic reactions, particularly in children and adolescents. Although such incidents remain rare, there are indications that MID is under-reported for many classes of medications.

Introduction

Dystonia is “a movement disorder (MD) characterized by involuntary sustained or intermittent muscle contractions, causing abnormal, often repetitive, movements, postures, or both” [1–7]. It is the third most common MD after essential tremor and Parkinson’s disease [2, 8, 9] and can affect any muscle group in the body (see Table 1) [1, 2, 4, 10]. Focal dystonias are the most common forms seen in clinical practice, involving the neck (cervical dystonia), the eyes (oculogyric crisis), the larynx (laryngeal dystonia), the mouth and jaw (oromandibular dystonia), or the limb (limb dystonia) [10–12]. Prevalence rates seem to be higher in female individuals for most types of dystonia [13].

Dystonia may be inherited, idiopathic, or acquired [1, 2, 5]. Acquired dystonias result from apparent outside factors and can be attributed to a specific cause, such as medications [2, 5, 14]. Medications most commonly associated with this type of MD are antipsychotics [5, 10, 15, 16]. However, dystonia may also occur with many other kinds of medication, such as antidepressants, lithium, antiepileptics, and calcium channel blockers [1, 14, 15, 17–19]. Medication-induced dystonia (MID) can be acute (occurring within hours to days of exposure to the drug), subacute (building up more slowly after days to weeks of exposure), or tardive [following long-term therapy (months-years) with the offending drug] [10, 20–30]. MID mostly resolves within a few hours or days with adequate treatment. However, in some cases, it can be persistent [10].

Existing lacunae in understanding the epidemiology and phenomenology of MID face clinicians with substantial challenges in the diagnosis and management of this drug-induced MD [31–33]. MID may be confused with different conditions such as partial seizure, encephalitis, tetanus, hysteria, or panic attacks. In exceptional cases (i.e. acute laryngeal dystonia), misdiagnosis can lead to a life-threatening situation [16, 23, 34–37]. Early identification, therefore, is essential.



Table 1. Classification of dystonia by body region [1, 2, 11].

Form	Definition
Focal	Involvement of one body region
Segmental	Involvement of two or more contiguous body regions
Multifocal	Involvement of two noncontiguous or more (contiguous or not) body regions
Generalized	The trunk and at least two other sites are involved

Until now, no extensive review on the epidemiology and phenomenology of MID across different non-antipsychotic medication groups has been conducted. Our objective therefore is to identify published evidence-based literature on the epidemiology and phenomenology of non-antipsychotic-induced dystonia in people without pre-existing MD by using a hybrid systematic-narrative strategy. This approach builds on the main components of both systematic and narrative reviews [38].

Methods

The protocol of this systematic-narrative review has been registered with the Open Science Framework initiative (<https://osf.io/uvpbn/>).

Search strategy

A comprehensive and systematic literature search (from inception to November 2023), using the PubMed and Embase databases, was conducted without language restriction for articles reporting on non-antipsychotic-induced dystonia in people without pre-existing MDs. One of the authors (JD) constructed search strings for both databases. Generic and brand drug names were used to identify cases of non-antipsychotic dystonia. Full search strategies are available as Supplementary Material. Articles, identified through PubMed and Embase, were imported into EndNote X9 and duplicates were removed [39]. After removing duplicates, titles and abstracts were screened by JD, using Rayyan QCRI. Articles that were deemed potentially relevant were selected. JD reviewed the full text of the selected articles and assessed their eligibility. Any doubts were solved by consensus or by the decision of a second and third reviewer (MDH, KC).

Selection criteria

All types of study designs were eligible for inclusion. Although observational studies, case series, and case reports have lower levels of evidence, we found it important to implement this kind of evidence, as (randomized) clinical trials have limited power to detect rarer events, such as motor side effects [40, 41]. Only articles providing information on the epidemiology and phenomenology of non-antipsychotic-induced dystonia in people (children, adolescents, adults, and elderly) without a pre-existing MD were selected. A narrative synthesis of the systematically retrieved eligible articles was made.

Results

The search yielded 58,326 articles. After removing duplicates ($n = 39,662$) a total of 718 systematic reviews and/or meta-analyses and 17,946 other records were screened for eligibility. Of these 40 systematic reviews and/or meta-analyses and 1,998 other records were identified as eligible.

For each non-antipsychotic medication group we will discuss, if this information is available, (1) epidemiology, (2) phenomenology [onset and form(s) of dystonia], (3) risk factors, and (4) agents that are specifically associated with an increased risk for dystonia. Among risk factors, race or ethnicity are not discussed as potential moderators. Although there are some studies that have indicated that for certain medications Asian patients may be more likely to experience MID, this has not been systematically studied.

Antiemetics and gastrointestinal drugs

Antiemetics are widely used to treat nausea and vomiting that can be caused by a variety of medical conditions and situations, such as chemotherapy, surgery, migraine, and pregnancy [42–49].

Metoclopramide can induce the entire phenomenological spectrum of dystonia, even with a single low dose [16, 24, 50–66]. Metoclopramide-induced acute dystonia has been seen in 0.2% up to 8.3% of adult cases [24, 44, 55, 57, 59, 67–76]. The risk can even be higher in children and elderly [54, 70, 77], and is increased at higher doses or with long-term treatment [75]. It typically occurs within 24–48 h of initiating treatment [59].

Given the known risk of MID with metoclopramide, particularly with chronic use or in young people, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) restricted the indications for metoclopramide to short-term use (up to 5 days). In children, it should only be used as a second-choice treatment [78, 79]. Metoclopramide (primarily metabolized by the cytochrome P450 enzyme CYP2D6) dosing should also be reduced in CYP2D6 poor metabolizers. It therefore should not be co-administered with strong CYP2D6 inhibitors [50, 80–83].

Acute or subacute dystonic reactions with *prochlorperazine*, first introduced as an antipsychotic in the 1950s [84], are seen in up to 4% of cases [68, 77, 85].

Several studies and case reports reported *promethazine*-induced acute dystonia in children and in pregnant women hospitalized for hyperemesis gravidarum [86–94]. Promethazine seems to be associated with a higher risk for dystonia, compared to metoclopramide [92, 93], sometimes inducing severe acute dystonic reactions (e.g. opisthotonus) in overdose cases [90]. In 2000, a warning section was added to the medication package insert stating that promethazine is contraindicated in children less than 2 years of age [91].

Dystonia is a very rare complication when using *domperidone* (0.01%), as it does not traverse the blood–brain barrier, unlike metoclopramide. Domperidone-induced acute dystonia usually occurs in infants and very young children (due to the poorly developed blood–brain barrier) or in the elderly [45, 46, 95–98].

At recommended clinical dosages, dystonic reactions associated with *levosulpiride* occur in less than 1% [98–101]. Levosulpiride-induced MDs seem to occur more frequently in the elderly, requiring strict pharmacovigilance [102, 103]. In exceptional cases, even the use of low-dose levosulpiride can lead to persistent dystonia [104, 105].

Although uncommon, some setrons also have also been associated with acute dystonic reactions in adults, as well as children. *Ondansetron*, for example, can induce the entire phenomenological spectrum of dystonia [49, 65, 106–120].

Clebopride, a dopamine receptor blocking agent (DRBA) which is 10 times more potent than metoclopramide [120] but marketed only in some countries, is associated with the occurrence of different types of dystonic reactions (oromandibular dystonia, blepharospasm, torticollis) [48, 65, 98, 121–126], particularly in younger people, even after one single dose [121].

Droperidol-induced acute dystonia has, with the exception of few, been reported in several studies [127–133] and case reports [65, 134–138] and can be severe and persistent [136].

Other commonly used antiemetics or gastrointestinal drugs that have been rarely associated with dystonic reactions are *cimetidine*, *ranitidine*, *cyclizine*, and *cisapride* [50, 106, 108, 139–148].

Antiepileptics

Antiepileptics (also known as antiseizure medications or anticonvulsants) are commonly prescribed for epilepsy/seizures prophylaxis or management, as well as for many other indications, such as bipolar disorder, anxiety, migraine, chronic pain, weight management, and insomnia [149].

The relationship between antiepileptics and MDs is complex. Although antiepileptics are used as a treatment for hyperkinetic MDs (specifically for tremor, myoclonus, and restless legs syndrome), several also have the potential to induce or worsen MDs, including dystonia [150, 151]. Four of these have been rarely (0.01 to 0.1%) associated with dystonia: valproate, carbamazepine, lamotrigine, and phenytoin. There have been more reports of MID with these agents in the middle-aged adult population.

Valproate is generally regarded as a first-choice agent for most forms of epilepsy, but it is also used to treat manic episodes, and as a medication for migraine prevention and impulse control [152]. Although tremor and parkinsonism are well-known side effects of valproate [150, 151, 153–155], dystonic reactions, most often subacute (> 3 weeks) and presenting as axial and cervical dystonia, have also been reported [151, 154]. Possible interactions with clozapine, risperidone, quetiapine, olanzapine, carbamazepine, ziprasidone, and butamirate citrate have been described [154].

Particularly children and adolescents seem to be susceptible to the development of *carbamazepine*-induced dystonia [156]. A recent systematic review identified 22 cases of carbamazepine-induced, mostly subacute (> 3 weeks), dystonia [151]. Generalized or segmental dystonia and oculogyric crises have been reported within normal and toxic plasma concentrations of carbamazepine. The combination of carbamazepine and isoniazid or lithium has been reported to induce oculogyric crisis and severe dystonic movements, including opisthotonos [150].

Lamotrigine, also used as a mood stabilizer for the treatment of bipolar disorder, most often is associated with the subacute (> 3 weeks) manifestation of blepharospasms, oculogyric crises, and oromandibular dystonia [150, 151, 157].

Mostly subacute (> 3 weeks) dystonic reactions have been reported with *phenytoin* at therapeutic and toxic serum levels [15, 151, 158–161]. The most common presentation seems to be upper limb dystonia.

Dystonia, although very rarely (<0.01%), has also been reported in association with *other antiepileptics* (see Table 2 for an overview of these antiepileptics), sometimes related to polymedication [162–164].

Antidepressants

Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are the most commonly prescribed types of antidepressant medication [165, 166]. These medications have a number of approved indications (such as major depression, obsessive compulsive disorder, and anxiety disorders) [167, 168], but are frequently used off-label as well. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are prescribed less often because they tend to cause more side effects.

Table 2. Higher risk medications that require special attention from healthcare professionals.

Medication class	Medication	Frequency ¹
Antiemetics and gastrointestinal drugs	Clebopride	Common
	Domperidone	Rare
	Metoclopramide	Common
	Prochlorperazine	Common
	Promethazine	Uncommon
Calcium antagonists (medication for migraine and dizziness)	Cinnarizine	Rare
	Flunarizine	Rare
Antiepileptics	Carbamazepine	Rare
	Phenytoin	Rare
	Lamotrigine	Rare
	Valproate and valproic acid	Rare
Antidepressants	Fluoxetine	Rare
	Fluvoxamine	Rare
	Paroxetine	Rare
Mood stabilizers	Lithium	Rare
ADHD medication	Methylphenidate (combined with an antipsychotic)	Rare

¹Very common (≥10%); common (≥1% to <10%); uncommon (≥0.1% to <1%); rare (≥0.01% to <0.1%).

Although uncommon, cases of antidepressant-induced acute and tardive dystonia have been observed and reported for decades [65, 139, 166, 168–180]. These side effects are seen more often with SSRIs than with SNRIs, TCAs, MAOIs, or other antidepressants [169, 173, 181, 182].

Selective serotonin reuptake inhibitors (SSRIs)

According to a review of Hawthorne & Caley [166], *citalopram*, *escitalopram*, *fluoxetine*, and *sertraline* are most frequently involved in dystonia cases. In 63% of the cases, dystonia occurred mostly subacute within 7 days of treatment initiation or dose increase (although acute or tardive dystonia cases have also been observed). Most cases of dystonia occurred in adult patients who have been receiving normal dosing and when a DRBA (mostly an antipsychotic) was added to the SSRI. Cases across the whole spectrum of dystonic reactions were observed. After the publication of this review several new cases of MID have been reported with sertraline and escitalopram, mostly in the adult population [167, 168, 174, 175, 183–186], but some of these also in the pediatric and adolescent population [167, 187–189].

An analysis of the WHO pharmacovigilance database found that the SSRIs fluoxetine, *fluvoxamine*, and *paroxetine* were statistically significantly associated with dystonia [173].

Serotonin and norepinephrine reuptake inhibitors (SNRIs)

Without providing specific information on dystonia cases, an analysis of FDA Adverse Event Reporting System cases [177], as well as a large epidemiological study [190] identified the SNRI *duloxetine*

as the antidepressant showing the highest association with EPS, compared with other antidepressants. A more recent analysis of MID reports in the WHO Pharmacovigilance database [173], however, showed no statistically significant association between duloxetine and dystonia.

Serotonin receptor antagonist and reuptake inhibitors (SARIs)

Trazodone, the prototype drug of this class of drugs, is approved for the treatment of major depressive disorder but is also commonly used off-label to treat insomnia or delirium, particularly in the elderly [170, 191]. Although only few cases have been reported in the scientific literature [170, 191–194], clinicians should be aware that long-term use of trazodone as a hypnotic, particularly when combined with an antipsychotic, such as risperidone, can cause tardive dystonia in elderly patients [191].

Serotonin and norepinephrine disinhibitors (SNDIs)

A literature review on *mirtazapine*, primarily used for the treatment of major depressive disorder, but also for several other off-label indications such as insomnia, migraine, and hot flushes, identified only five cases of dystonia (particularly in the elderly) [195].

Tricyclic antidepressants (TCAs)

Although less common than with SSRIs, dystonia cases have been reported with the TCAs *amitriptyline*, *amoxapine*, *doxepin*, *imipramine*, and *clomipramine* [65, 173, 182, 196–198]. According to a review of 48 reports, examining the link between amitriptyline and MDs, patients with amitriptyline-induced dystonia ($n = 19$) tended to be younger and were prescribed a lower dose of amitriptyline [197]. A postmarketing study in the world pharmacovigilance database [173] found that amoxapine is the TCA associated with the highest risk for dystonia. It may induce several forms of subacute and tardive dystonia, including cervical dystonia and oculogyric crisis [199–201].

Monoamine oxidase inhibitors (MAOIs)

EPS (including dystonia) have infrequently been reported during treatment with MAOIs [173, 182]. According to a postmarketing study in the world pharmacovigilance database [173], none of the studied MAOIs (isocarboxazid, phenelzine, tranylcypromine, moclobemide) was significantly associated with dystonia. Despite this, acute and subacute forms of dystonia have been reported with *tranylcypromine* (truncal dystonia) and *phenelzine* (oculogyric crisis and cervical dystonia), respectively [202, 203].

Combination drugs

Although most GPs are aware that antipsychotics can induce EPS, they may be less aware that patients treated with a combination drug¹, including an antipsychotic, may also be at risk to develop dystonia. One such example is a combination of the first-generation antipsychotic flupentixol (0.5 mg) and the tricyclic antidepressant melitracen (10 mg). Many GPs and neurologists prescribe this

medication for depression, anxiety, or neurotic symptoms [204–206], for example in patients with irritable bowel syndrome [205]. Although no cases of dystonia in the scientific literature have been identified with this combination drug, there are indications that dystonia can be induced with long-term daily use of this medication (personal communication). Moreover, this combination drug is not approved for use and marketing in several developed countries, including the United States and the United Kingdom [204]. In India, it was even banned [207]. Although still registered in Belgium, the Belgian Centre for Pharmacotherapeutic Information strongly advises against using this combination drug to treat patients with depression.

Lithium

A recent review [208] found dystonia to be the fourth most common MD with *lithium* (after parkinsonism, dyskinesia, and myoclonus). Twenty-two of the 436 identified MD cases concerned individuals who developed all forms of dystonia (including blepharospasm, oromandibular, cervical, distal segmental, axial, and lingual dystonia). Interestingly, one of every two individuals developing lithium-induced dystonia was from Asia. These patients were also significantly younger than the subjects presenting other MDs. The onset of dystonia varied between 1 day and 25 years. In about one-fourth of the identified cases, an antipsychotic was used. However, it is important to recognize dystonia as a potential complication of lithium, not only when administered in combination with an antipsychotic, but even when it is used as monotherapy or combined with small doses of other non-DRBA, especially during long-term use [209–211].

Stimulants

Methylphenidate (MPH) is often used as a treatment for children and adolescents with ADHD with or without comorbid conduct-disorder [212]. Most reported MPH-induced dystonia cases in children and adolescents have occurred after initiation or up-titration of MPH. These cases involved MPH monotherapy [213] and combined MPH-second generation antipsychotic treatment [41, 214, 215]. A review of case reports and an analysis of the WHO pharmacovigilance database on the occurrence of MDs in children and adolescents using a combination therapy of MPH and the antipsychotic risperidone identified 4 case reports and 32 individual case safety reports (ICSRs) describing dystonic movements in relation to the combination therapy. Among the ICSRs, dystonia was the second most reported MD, and cases across the whole spectrum of dystonic reactions were observed [41]. Dystonia with MPH has also been reported in combination with other antipsychotics and medications known to have a risk of inducing dystonia (aripiprazole, propofol) [216], after prolonged use [212], or in the context of MPH withdrawal during psychostimulant detoxification [217].

Antihistamines

MID due to the use of antihistamines has been very rarely reported [47, 218–222].

Cetirizine is a frequently used antihistamine for the treatment of allergic disorders in children. Several cases of cetirizine-induced acute (even after a single oral dose at recommended dosages), subacute, or tardive dystonia, such as oculogyric crisis, cervical,

¹Medications that include two or more active ingredients combined in a single form at a fixed dose, of which at least one is associated with an increased risk of dystonic reactions.

and oromandibular dystonia, in (mostly) children and adults, have been reported in the literature [47, 65, 218, 221–223].

Despite its widespread use in the management of MID [224], the first-generation antihistaminergic *diphenhydramine*, paradoxically, has also been recognized as a contributor to acute dystonia in very rare cases. The onset of dystonic reactions is usually rapid, developing shortly after taking the antihistamine. However, such reactions may also occur after long-term therapy. Patients characteristically develop facial dystonia, torticollis, and extremities dystonia [225–231].

Although very uncommon (but probably more common than reported) [225], MID with cough and cold preparations having antihistaminic properties (such as the widely used *cloperastine*-based cough syrup), has also been described. Oculogyric crisis and torticollis are among the most frequent dystonic reactions, with children being more susceptible than adults [218, 225, 232].

Finally, few cases of dystonia following *hydroxyzine* administration (widely used for skin allergies) have been reported [233, 234].

It is likely that the risk of MID increases when antipsychotics and (preparations containing) antihistamines are administered concomitantly, particularly in vulnerable individuals (e.g. chronic pretreatment with anti-dopaminergic drugs) [225, 235].

Calcium channel blockers

Calcium channel blockers (CCBs) are medicines that are most often used to treat conditions of the heart and blood vessels, such as hypertension, angina, and cardiac arrhythmias. Besides these indications, they are also frequently prescribed for the treatment of migraine, vertigo, and cerebrovascular insufficiency [236].

Most CCB-induced MDs are reported with *flunarizine* and *cinnarizine*. According to an analysis of patients who have been taking flunarizine ($n = 26,133$) or cinnarizine ($n = 7,186$) for more than 1 month, both agents significantly increased the risk of subacute or tardive dystonia [incidence rates of flunarizine- and cinnarizine-induced dyskinesia/dystonia were 1.21(0.81–1.78) and 1.52(0.79–2.92) per 10,000 person months, respectively]. However, as many of the patients in this study used antipsychotics or metoclopramide concomitantly, the risk of flunarizine- or cinnarizine-related MDs might have been overestimated [237]. In the study of Fabiani et al. [238] dystonia was diagnosed in 4% of the patients due to the chronic use of cinnarizine and flunarizine. Flunarizine-related MDs (including dystonia) are associated with a high-dose exposure, longer exposure duration, older age, history of essential tremor, and cardiovascular diseases [236].

Some case reports described acute and tardive (persistent) dystonic reactions induced by the CCBs *verapamil* [239–241], *nifedine* [242, 243], and *amlodipine* (inducing cranial, cervical, pharyngo-laryngeal, or axial dystonia) [18], and the antiarrhythmic drug *flecainide* [244].

Antimalarials

Acute dystonia (oromandibular dystonia and oculogyric crisis) induced by *chloroquine*, commonly used for both the prevention and treatment of malaria, is very rare [139, 245, 246]. It mainly has been reported after a single dose of chloroquine, in the presence [247] (particularly in combination with the common antibiotic metronidazole) [248] or absence of other medications [246].

There are some case-reports of *artesunate/amodiaquine* and *artemether/lumefantrine*-induced acute dystonia (oculogyric crisis) in

the literature [248, 249]. Artemether/lumefantrine treatment may cause dystonic reactions in patients at any age, even at therapeutic dosages [250].

Other medications

Dystonic reactions, although rarely observed, have been reported with several *antibiotics* [65, 243, 251–265] and *antiviral drugs* [266, 267] (see Table 3), which usually are acute and may involve the whole spectrum of dystonia. Many other medications have been found to induce dystonia (particularly when used in combination with other agents), in most cases involving the head and neck: several *opioid analgesics* (e.g. fentanyl) [21, 139, 243, 268–271], the *non-opioid anesthetic* propofol [21, 113, 139, 233, 268, 272–280] (sometimes inducing full opisthotonus or laryngeal dystonia), the *inhalational anesthetic* sevoflurane (particularly associated with an increased risk of laryngospasm, potentially leading to laryngeal dystonia, especially in children) [21, 269, 281–288], the *analgesic and antipyretic drug* paracetamol (although acute dystonia with therapeutic doses of paracetamol is very unusual) [288], several *antitussives* [225, 232, 235, 289–293] (often associated with cervical dystonia), the *anthelmintic drug* albendazole (particularly in sensitive children) [294, 295], the *histamine analog* betahistine (largely used in the treatment of Ménière's disease and also having the propensity to induce tardive dystonia after prolonged use) [296–298], the *cytostatic drug* capecitabine [299–301] (typically associated with oromandibular dystonia), *tetrabenazine* (a medication mainly used in patients with hyperkinetic MDs, including dystonia, that may, however, worsen dystonia particularly in vulnerable young adults) [65, 139, 302–305], *isotretinoin* (a medication used to treat severe acne that can induce oculogyric crisis) [306], and the *immunosuppressant agents* cyclosporine (rarely causing limb or focal hand dystonia that may persist after cyclosporine withdrawal) [307, 308] and tacrolimus (strongly associated with dystonia, particularly in female pediatric patients) [309]. Concerning analgesic-induced dystonia particularly female patients seem to be vulnerable, as women might respond differently to general anesthetic agents, compared to men [310]. *Cholinesterase inhibitors*, widely used in patients with Alzheimer's disease and in patients with myasthenia gravis, seem to be particularly associated with the Pisa Syndrome, also known as pleurothotonus, a term used to describe a type of acute or tardive truncal dystonia [65, 311–318]. Finally, several *benzodiazepines* have been associated with acute and tardive dystonia (including opisthotonus) in adults and children [319–322] (See Table 3). For example, long-term use of etizolam, zolpidem, and brotizolam may result in blepharospasms, especially in women [323, 324].

Discussion

The rates of MID probably are underestimated [102, 325, 326]. The Hannover epidemiology study [11], which considered all forms of dystonia (including DRBA-induced dystonia) in highly specialized centers, estimated dystonia rates to be at least four times higher than previously thought. There are indications that dystonia is also underreported for several other classes of medications, including antidepressants, antiemetics, and cholinesterase inhibitors [63, 75, 173, 175, 180, 318, 325]. Revet et al. [173], for example, identified 5,113 dystonia cases (0.50%) (on a total of 1,027,405 reported cases containing at least one of the 58 selected antidepressant drugs) in the WHO pharmacovigilance database during the time period of January 1967 to February 2017. This means that the prevalence of

Table 3. Medications very rarely (<0,01%) associated with dystonia or for which this risk cannot be precisely estimated.

Medication class	Medication
Antibiotics	Cefalexine
	Cefepime
	Cefixime
	Cefuroxime
	Ciprofloxacin
	Erythromycin
	Gemifloxacin
	Levofloxacin
	Metronidazole
	Spiramycin
Antiemetics and gastrointestinal drugs	Cimetidine
	Cisapride
	Itopride
	Ondansetron
	Ranitidine
	Tropisetron
Antidepressants	Amitriptyline
	Amoxapine
	Bupropion
	Citalopram
	Clomipramine
	Doxepin
	Duloxetine
	Escitalopram
	Flupentixol-Melitracen (!!!)
	Imipramine
	Mirtazapine
	Sertraline
	Venlafaxine
	Trazodone
Antiepileptics	Clobazam
	Felbamate
	Gabapentin
	Midazolam
	Oxcarbazepine
	Perampanel
	Phenobarbital
	Pregabalin
	Tiagabine
	Topiramate
	Vigabatrin
Cholinesterase inhibitors	Donepezil
	Galantamine
	Rivastigmine

Continued

Table 3. *Continued*

Medication class	Medication
Opioid analgesics	Fentanyl
	Meperidine
	Morphine
	Pentazocine
Analgesics and antipyretics	Paracetamol
Antitussives	Butamirate citrate
	Cloperastine
	Codeine
	Dextromethorphan (although almost none of the cases of dextromethorphan-induced dystonia has been reported within the therapeutic range)
Calcium antagonists	Nifedipine
	Amlodipine
	Verapamil
	Flecainide
Anesthetics	Nitric oxide
	Propofol (particularly with certain propofol combination regimens that include either ketamine or dexmedetomidine)
	Sevoflurane (particularly when administered in combination with an antipsychotic)
Antiallergics	Cetirizine
	Diphenhydramine
	Hydroxyzine
Antivirals	Foscarnet
	Lamivudine
Antimalarials	Artesunate/amodiaquine
	Hydroxychloroquine
	Artemether/lumefantrine
Sleep medication, sedatives, and anxiolytics (mostly long-term use)	Bromazepam (BDZ)
	Brotizolam (BDZ)
	Clobazam (BDZ)
	Midazolam (BDZ)
	Diazepam (BDZ)
	Zolpidem
	Etizolam
Retinoids	Isotretinoin
Cytostatics	Capecitabine
Anthelmintics	Albendazole
Histamine analogs	Betahistine
Vesicular monoamine transporter 2 (VMAT2) inhibitors	Tetrabenazine
Immunosuppressive agents	Cyclosporine
	Tacrolimus

BDZ: Benzodiazepine

(!!!): Belgian Centre for Pharmacotherapeutic Information strongly advises against the use of this medication

dystonia for antidepressants, as a group, lies between $\geq 0.1\%$ to $<1\%$ (= uncommon side effect), while the frequency of this side effect for each antidepressant has been rated by the authors of this article as rare or very rare (see [Tables 2 and 3](#)).

There are several reasons why MID might be underreported. Firstly, only few individual studies or systematic reviews/meta-analyses on medication-induced EPS mention dystonia as a separate category because of the smaller numbers of this MD, compared

to these for other MD, such as dyskinesia, akathisia, or parkinsonism. Secondly, although it is generally well-known to GPs that dystonia is commonly associated with the use of DRBAs such as high-potency antipsychotics, they do not expect it to be an adverse drug reaction (ADR) associated with medications widely used in general clinical practice, such as antidepressants, antibiotics, antivirals, antiallergics, and antitussives. Moreover, many GPs are not familiar with the clinical presentation of acute dystonia. This leads to a higher likelihood of misdiagnosis [325]. Finally, the severity spectrum of dystonia can be extremely large. Dystonia might be a subtle finding, rather than a complaint, without a serious consequence for the patient [11]. Under these circumstances, GPs may interpret this ADR as not important. However, in exceptional cases (i.e. laryngeal dystonia) MID can be life-threatening [20, 31, 37, 277, 327–336]. The patient can develop acute respiratory distress through upper airway obstruction showing signs, such as cyanosis, stridor, gasping, and an inability to manage secretions [34, 211, 337, 338]. Acute laryngeal dystonia can easily be misdiagnosed as anaphylaxis, epiglottitis, hysteria, panic attack, or acute anxiety [23, 34–36]. Prompt recognition therefore can save lives. The sudden onset of symptoms with rapid progression in the presence of a dystonia risk profile should caution the health professional [339]. Characteristic symptoms of laryngeal dystonia are dyspnea, laryngeal stridor, and extreme distress. Laryngeal dystonia may also be accompanied by dystonia in other parts of the body [31, 37].

The treatment of dystonia typically involves discontinuing the offending drug (due to the risk of a recurrent dystonic reaction) and administration of medications that block the acetylcholine receptors (i.e. anticholinergics, benzodiazepines, and certain antihistamines) [11, 20, 24, 327]. However, symptoms may reoccur within hours after initial treatment. In these cases, clinicians should give another dose of the medication or administer the medication for several days to prevent the reoccurrence of dystonia [327, 340].

Supplementary material. The supplementary material for this article can be found at <http://doi.org/10.1192/j.eurpsy.2025.18>.

Financial support. This work has been financed by the fund secondary dystonia, managed by the King Baudouin Foundation Belgium, Brederodestraat 21, 1000 Brussels, under grant agreement no 2023-j5210910–230851 (<https://kbs-frb.be/en/fund-secondary-dystonia>) [341], and by an unrestricted grant from Johnson & Johnson, Lundbeck and Eli Lilly.

Competing interest. The authors declare that there are no conflicts of interest relevant to this work [342].

References

- [1] Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. *Mov Disord.* 2013;28(7):863–73.
- [2] Grütz K, Klein C. Dystonia updates: definition, nomenclature, clinical classification, and etiology. *J Neural Transm (Vienna).* 2021;128(4):395–404.
- [3] Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. *J Neurol Sci.* 2018;389:10–6.
- [4] Snaith A, Derick W. Dystonia. *BMJ Clin Evid.* 2014;2014:1211.
- [5] van Egmond ME, Lagrand TJ, Lizaitiene G, Smit M, Tijssen MAJ. A novel diagnostic approach for patients with adult-onset dystonia. *J Neurol Neurosurg Psychiatry.* 2022;93(10):1039–48.
- [6] Oppenheim H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (Dysbasia lordotica progressiva, Dystonia musculorum deformans). *Neurol Centrbl.* 1911;30:1090–107.
- [7] Klein C, Fahn S. Translation of Oppenheim's 1911 paper on dystonia. *Mov Disord.* 2013;28(7):851–62.
- [8] Pana A, Saggi BM. Dystonia [2022, Sep 5]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023, Jan. PMID: 28846290.
- [9] Stephen CD. The dystonias. *Continuum (Minneapolis Minn).* 2022;28(5):1435–75.
- [10] Rissardo JP, Vora N, Mathew B, Kashyap V, Muhammad S, Fornari Caprara AL. Overview of movement disorders secondary to drugs. *Clin Pract.* 2023;13(4):959–76.
- [11] Dressler D, Altenmüller E, Giess R, Krauss JK, Adib Saberi F. The epidemiology of dystonia: the Hannover epidemiology study. *J Neurol.* 2022;269(12):6483–93.
- [12] Karp BI, Alter K. Muscle selection for focal limb dystonia. *Toxins (Basel).* 2017;10(1):20.
- [13] Kilic-Berkmen G, Scorr LM, McKay L, Thayani M, Donsante Y, Perlmutter JS, et al. Sex differences in dystonia. *Mov Disord Clin Pract.* 2024;11(8):973–82.
- [14] Dystonia Medical Research Foundation Canada. What is dystonia? <https://dystoniacanada.org/about-dystonia/>. Last Access: May 14, 2024; 2023.
- [15] Chouksey A, Pandey S. Clinical spectrum of drug-induced movement disorders: a study of 97 patients. *Tremor Other Hyperkinet Mov (NY).* 2020;10:48.
- [16] Park HW, Kwak JR, Lee JS. Clinical characteristics of acute drug-induced dystonia in pediatric patients. *Clin Exp Emerg Med.* 2017;4(3):133–7.
- [17] Friedman JH. Movement disorders induced by psychiatric drugs that do not block dopamine receptors. *Parkinsonism Relat Disord.* 2020;79:60–4.
- [18] Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. *J Neural Transm (Vienna).* 2014;121(4):367–9.
- [19] Dressler D. Nonprimary dystonias. *Handb Clin Neurol.* 2011;100:513–38.
- [20] Duma SR, Fung VS. Drug-induced movement disorders. *Aust Prescr.* 2019;42(2):56–61.
- [21] Burkhard PR. Acute and subacute drug-induced movement disorders. *Parkinsonism Relat Disord.* 2014;20 Suppl 1:S108–12.
- [22] Tural Hesapcioglu S, Ceylan MF, Kandemir G, Kasak M, Sen CP, Correll CU. Frequency and correlates of acute dystonic reactions after antipsychotic initiation in 441 children and adolescents. *J Child Adolesc Psychopharmacol.* 2020;30(6):366–75.
- [23] Collins N, Sager J. Acute laryngeal dystonia: drug-induced respiratory failure related to antipsychotic medications. *J Neurol Neuromedicine.* 2018; 3(1): 4–7.
- [24] Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. *Headache.* 2016;56(1):153–61.
- [25] Grabel M, Merola A. Pallidal deep brain stimulation for tardive dystonia: meta-analysis of clinical outcomes. *Neurol Sci.* 2023;44(3):827–33.
- [26] Factor SA. Management of tardive syndrome: medications and surgical treatments. *Neurotherapeutics.* 2020;17(4):1694–712.
- [27] Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. *Brain.* 1998; 121(Pt 11):2053–66.
- [28] Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. *Mov Disord.* 1986;1(3):193–208.
- [29] Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. *Neurology.* 1982;32(12):1335–46.
- [30] Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. *Mov Disord.* 2012;27(14):1789–96.
- [31] O'Neill JR, Stephenson C. Antipsychotic-induced laryngeal dystonia. *Psychopharmacol Bull.* 2022;52(1):61–7.
- [32] Sadnicka A, Meppelink AM, Kalinowski A, Oakeshott P, van den Dool J. Dystonia. *BMJ.* 2022;377:e062659.
- [33] Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. *Neurol Clin.* 2011;29(1):127–48, viii.
- [34] Alkharboush GA, Alsalamah MA. Risperidone-induced acute laryngeal dystonia: a case report. *Am J Case Rep.* 2020;21:e922393.

- [35] Mellacheruvu S, Norton JW, Schweinfurth J. Atypical antipsychotic drug-induced acute laryngeal dystonia: 2 case reports. *J Clin Psychopharmacol.* 2007;27(2):206–7.
- [36] Chakravarty A. Neuroleptic-induced acute laryngeal dystonia causing stridor: a lesson to remember. *Mov Disord.* 2005;20(8):1082–3.
- [37] Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. *J Psychopharmacol.* 2005; 19(3):307–11.
- [38] Turnbull D, Chugh R, Luck J. Systematic-narrative hybrid literature review: a strategy for integrating a concise methodology into a manuscript. *Soc Sci Human Open.* 2023;7(1):100381.
- [39] Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in end note. *J Med Libr Assoc.* 2016;104(3):240–3.
- [40] Straus SE, Glasziou P, Richardson WS, Haynes RB, Pattani R, Veroniki AA. Evidence-based medicine: how to practice and teach EBM. 5th ed. Edinburgh/London/New York/Oxford/Philadelphia/St. Louis/Sydney: Elsevier; 2019.
- [41] Stämpfli D, Weiler S, Burden AM. Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. *Eur Child Adolesc Psychiatry.* 2021;30(7):1047–58.
- [42] LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Antiemetic Agents. [Updated 2018 Jan 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548071/>. Last Access: September 6, 2024.
- [43] Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. *Aust Prescr.* 2020;43(2):49–56.
- [44] Kelley NE, Tepper NE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. *Headache.* 2012;52(2):292–306.
- [45] Daripa B, Lucchese S. A rare case of domperidone-induced acute dystonia in a young adult due to consumption of combination drug (proton pump inhibitors with domperidone) and its possible pathomechanism. *Cureus.* 2022;14(4):e23723.
- [46] Shahbaz A, Elahi K, Affan M, Shahid MF, Sabir A. Acute dystonia secondary to domperidone in a pediatric patient. *Cureus* 2018;10:e3587.
- [47] Sharawat IK, Dawman L. Acute focal dystonia after a single dose of oral cetirizine in a 9-year-old boy. *Pediatr Emerg Care.* 2019;35(2):e30–1.
- [48] Choi JK, Hong JY. Acute cervical dystonia induced by clebopride. *Case Rep Neurol Med.* 2017;2017:2834349.
- [49] Kwon KT, Rudkin SE, Langdorf MI. Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians. *Clin Pediatr (Phila).* 2002;41(9):641–52.
- [50] Fink FM, Bogner M, Hengl P, Paulmichl M, Nofziger C. Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers. *Front Pharmacol.* 2023;14:1201566.
- [51] Isola S, Hussain A, Dua A, Singh K, Adams N. Metoclopramide. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519517/>. Last Access: 6 September 2024; [Updated 2023 September 4]
- [52] Sun L, Xi Y, Wen X, Zou W. Use of metoclopramide in the first trimester and risk of major congenital malformations: a systematic review and meta-analysis. *PLoS One.* 2021;16(9):e0257584.
- [53] Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. *N Engl J Med.* 2009;360(24):2528–35.
- [54] MEDSAFE (New Zealand Medicines and Medical Devices Safety Authority). Metoclopramide: risk of dystonic side effects in children and young adults. Prescriber Update. 2023;44(1):8–10.
- [55] Chaudhary R, Malla G, Kadayat M. Metoclopramide-induced acute dystonic reactions: a case report. *J Med Case Rep.* 2021;15(1):520.
- [56] Tianyi FL, Agbor VN, Njim T. Metoclopramide induced acute dystonic reaction: a case report. *BMC Res Notes.* 2017;10(1):32.
- [57] Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. *Br Med J (Clin Res Ed).* 1985;291(6500):930–2.
- [58] Chicella MF, Batres LA, Heesters MS, Dice JE. Prokinetic drug therapy in children: a review of current options. *Ann Pharmacother.* 2005;39(4):706–11.
- [59] Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. *Expert Rev Endocrinol Metab.* 2010;5(5):653–62.
- [60] Abdelmonem H, Abdelhay HM, Abdelwadoud GT, Alhosini ANM, Ahmed AE, Mohamed SW, et al. The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. *BMC Neurol.* 2023;23(1):221.
- [61] van Dooijeweert B, Verschuur AVD, Visser NA, Jansen J. Een peuter met een status dystonicus door medicatie [A toddler with status dystonicus due to medication]. *Ned Tijdschr Geneesk.* 2021;165:D5470.
- [62] El Ç, Çelikkaya ME. Varied clinical presentations of acute dystonic reaction due to metoclopramide. *Pediatr Emerg Care.* 2019;35(5):369–72.
- [63] Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide. *Nat Clin Pract Gastroenterol Hepatol.* 2006;3(3):138–48.
- [64] Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. *Pediatrics.* 2006; 118(2):746–52.
- [65] Barow E, Schneider SA, Bhatia KP, Ganos C. Oculogyric crises: etiology, pathophysiology and therapeutic approaches. *Parkinsonism Relat Disord.* 2017;36:3–9.
- [66] Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. *BMJ.* 2004;329(7479):1369–73.
- [67] Šarac I, Šarac H, Božina T, Šimičević L, Borovečki F, Henigsberg N, et al. Metoclopramide-induced acute dystonic reaction in two patients, cyp2d6 *4/*4, *10/*10 (poor) and *1/*5 (intermediate) metabolizers. *Psychiatr Danub.* 2023 Summer;35(2):269–71.
- [68] Kirkpatrick L, Sogawa Y, Cleves C. Acute dystonic reactions in children treated for headache with prochlorperazine or metoclopramide. *Pediatr Neurol.* 2020;106:63–4.
- [69] Marano M, di Biase L, Salomone G, Di Santo A, Montirola A, Di Lazzaro V. The clinical course of a drug-induced acute dystonic reaction in the emergency room. *Tremor Other Hyperkinet Mov (NY).* 2016;6:436.
- [70] Valkova M, Stamenov B, Peychinska D, Veleva I, Dimitrova P, Radeva P. Metoclopramide – induced extrapyramidal signs and symptoms – brief review of literature and case report. *J of IMAB.* 2014;20(6):539–41.
- [71] Karagoz G, Kadanali A, Dede B, Anadol U, Yucel M, Bektasoglu MF. Metoclopramide-induced acute dystonic reaction: a case report. *Eurasian J Med.* 2013;45(1):58–9.
- [72] Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. *Cephalalgia.* 2005;25(3):199–204.
- [73] Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. *Ann Emerg Med.* 1995; 26(5):541–6.
- [74] Bateman DN, Darling WM, Boys R, Rawlins MD. Extrapyramidal reactions to metoclopramide and prochlorperazine. *Q J Med.* 1989;71(264): 307–11.
- [75] Sheikh Hassan M, Ahmed Nor M. Metoclopramide induced acute dystonic reaction: a case report. *Ann Med Surg (Lond).* 2022;74:103248.
- [76] Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of metoclopramide in children: a systematic review and meta-analysis. *Drug Saf.* 2016;39(7):675–87.
- [77] Olsen JC, Keng JA, Clark JA. Frequency of adverse reactions to prochlorperazine in the ED. *Am J Emerg Med.* 2000;18(5):609–11.
- [78] European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. Changes aim mainly to reduce the risk of neurological side effects. 2013, December 20. EMA/13239/2014 Corr. 1. <https://www.ema.europa.eu/en/medicines/human/referentials/metoclopramide-containing-medicines>. Last access: September 6, 2024.
- [79] Nagel JM, Ghika J, Runge J, Wolf ME, Krauss JK. Case report: pallidal deep brain stimulation for treatment of tardive dystonia/dyskinesia

- secondary to chronic metoclopramide medication. *Front Neurol.* 2023; 13:1076713.
- [80] Zhou Q, Yan XF, Zhang ZM, Pan WS, Zeng S. Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. *World J Gastroenterol.* 2007;13(42):5618–28.
- [81] van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. *Neth J Med.* 2006;64(5):160–2.
- [82] Chua EW, Harger SP, Kennedy MA. Metoclopramide-induced acute dystonic reactions may be associated with the CYP2D6 poor metabolizer status and pregnancy-related hormonal changes. *Front Pharmacol.* 2019; 10:931.
- [83] van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. *Neth J Med.* 2006;64(5):160–2.
- [84] Manteuffel J. Use of antiemetics in children with acute gastroenteritis: are they safe and effective? *J Emerg Trauma Shock.* 2009;2(1):3–5.
- [85] Golikhatir I, Cheraghmakani H, Bozorgi F, Jahanian F, Sazgar M, Montazer SH. The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis. *Headache.* 2019; 59(5):682–700.
- [86] Southard BT, Al Khalili Y. Promethazine. [Updated 2024 Jan 1]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024, January. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK544361/> Last Access: 6 September, 2024.
- [87] Zhang R, Lai J, Huang J. Acute onset of orofacial dystonia from promethazine treatment: a case report. *Medicine (Baltimore).* 2019;98(43): e17675.
- [88] Cantisani C, Ricci S, Grieco T, Paolino G, Faina V, Silvestri E, et al. Topical promethazine side effects: our experience and review of the literature. *Biomed Res Int.* 2013;2013:151509.
- [89] DeGrandi T, Simon JE. Promethazine-induced dystonic reaction. *Pediatr Emerg Care.* 1987;3(2):91–2.
- [90] Darwish H, Grant R, Haslam R, Roth S. Promethazine-induced acute dystonic reactions. *Am J Dis Child.* 1980;134(10):990–1.
- [91] Starke PR, Weaver J, Chowdhury BA. Boxed warning added to promethazine labeling for pediatric use. *N Engl J Med.* 2005;352(25):2653.
- [92] Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. *Obstet Gynecol.* 2010;115(5):975–81.
- [93] Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* 2018; 31(18):2492–505.
- [94] Malamed SF, ed. Sedation. A guide to patient management. Elsevier, p. 632; 2016.
- [95] Junqueira DR, Bennett D, Huh SY, Fahrbach K, Neupane B, Betts M. Risk of adverse events associated with domperidone and metoclopramide in gastroparesis: systematic review and meta-analysis. *Drugs R D.* 2023; 23(1):1–20.
- [96] Tang KL, Mokhti FA, Fong JY, Anwar HK. Domperidone-related acute dystonia in a young child with underlying abnormal electroencephalogram. *Int J Clin Pediatr* 2020;9(2):55–8.
- [97] Dhakal OP, Dhakal M, Bhandari D. Domperidone-induced dystonia: a rare and troublesome complication. *BMJ Case Rep.* 2014;2014: bcr2013200282.
- [98] Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. *Aliment Pharmacol Ther.* 2004;19(4):379–90.
- [99] Bhattaram S, Shinde VS. Single dose levosulpiride induced acute dystonic reaction. *Med J DY Patil Vidyapeeth.* 2022;15(6):926–7.
- [100] Joe J. Levosulpiride-induced neurological adverse effects: a prospective study from a tertiary care center. *Ann Indian Acad Neurol.* 2020;23(2): 174–6.
- [101] Choudhury S, Chatterjee K, Singh R, Shubham S, Trivedi S, Chatterjee S, et al. Levosulpiride-induced movement disorders. *J Pharmacol Pharmacother.* 2017;8(4):177–81.
- [102] Anand R, Pandey S, Garg RK, et al. Phenomenology, quality of life, and predictors of reversibility in patients with drug-induced movement disorders: a prospective study. *CNS Spectr.* 2023;28(5):534–6.
- [103] Radhakrishnan DM, Goyal V. Levosulpiride-induced movement disorders: a compelling case for prudent use! *Ann Indian Acad Neurol.* 2021;24(2):300–1.
- [104] Letters to the Editor. *Br J Psychiatr.* 2007;190:81.
- [105] Radhakrishnan DM, Goyal V. Levosulpiride-induced dystonia: 7 cases. *J Assoc Physicians India.* 2018;66(6):95–6.
- [106] Aggarwal A, Bhatt M. Commonly used gastrointestinal drugs. *Handb Clin Neurol.* 2014;120:633–43.
- [107] Teoh L, Allen H, Kowalenko N. Drug-induced extrapyramidal reactions. *J Paediatr Child Health.* 2002;38(1):95–7.
- [108] Dieckmann K, Maurage C, Rolland JC, Ramponi N, Jonville AP. Torticollis as a side effect of cisapride treatment in an infant. *J Pediatr Gastroenterol Nutr.* 1996;22(3):336.
- [109] Cinar E, Sanci E, Utku HS, Ozbek AE. Ondansetron-induced oculogyric crisis in a pediatric patient: case report. *CJEM.* 2023;25(6):534–6.
- [110] Burstein B, Rogers S, Klassen TP, Freedman SB. Trends in management of children with acute gastroenteritis in US emergency departments. *JAMA Netw Open.* 2022;5(5):e2211201.
- [111] Freedman SB, Hall M, Shah SS, Kharbanda AB, Aronson PL, Florin TA, et al. Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. *AMA Pediatr.* 2014;168(4):321–9.
- [112] Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. *Obstet Gynecol.* 2014;123(6):1272–9.
- [113] Elhusseiny AM, Grush A, Dagi LR. Acute, severe dystonia after strabismus surgery in a patient on propofol, ondansetron, and bupropion. *J AAPOS.* 2020;24(5):312–4.
- [114] Kulkarni R. A severe postoperative dystonic reaction to ondansetron. *Anaesthesia Cases* 2015;3(1):73–5.
- [115] Macachor JD, Kurniawan M, Loganathan SB. Ondansetron-induced oculogyric crisis. *Eur J Anaesthesiol.* 2014;31(12):712–3.
- [116] Size MH, Rubin JS, Patel A. Acute dystonic reaction to general anesthesia with propofol and ondansetron: a graded response. *Ear Nose Throat J.* 2013;92(1):E16–8.
- [117] Patel A, Mittal S, Manchanda S, Puliyl JM. Ondansetron-induced dystonia, hypoglycemia, and seizures in a child. *Ann Pharmacother.* 2011; 45(1):e7.
- [118] Lee CY, Ratnapalan S, Thompson M, Nathan PC, Closs J, French A, et al. Unusual reactions to 5-HT₃ receptor antagonists in a child with rhabdomyosarcoma. *Can J Clin Pharmacol.* 2010;17(1):e1–4.
- [119] Ramakrishna H, Trentman TL, Hall BA, Sprung J. Ondansetron and carpopedal spasm. *Can J Anaesth.* 2008;55(1):55–6.
- [120] Tolan MM, Fuhrman TM, Tsueda K, Lippmann SB. Perioperative extrapyramidal reactions associated with ondansetron. *Anesthesiology.* 1999; 90(1):340–1.
- [121] Seo YW, Ko SH, Jang TC, Kim GM. Acute dystonic reaction induced by a single dose of clebopride: a case report. *Medicine (Baltimore).* 2019; 98(22):e15826.
- [122] Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, Catalán MJ, Zurdo M, Burguera JA, et al. Drug-induced tardive syndromes. *Parkinsonism Relat Disord.* 1999;5(1–2):59–65.
- [123] Sempere AP, Mola S, Flores J. Dystonia tardía tras la administración de clebopride [Tardive dystonia following the administration of clebopride]. *Rev Neurol.* 1997;25(148):2060.
- [124] Bosco D, Plastino M, Marcello MG, Mungari P, Fava A. Acute hemifacial dystonia possibly induced by clebopride. *Clin Neuropharmacol.* 2009; 32(2):107–8.
- [125] Kim W, Lee KS, Kim YI, Kim JS. Acute oculogyric crisis in a patient taking clebopride. *Intern Med.* 2008;47(6):551–2.
- [126] Corominas Sánchez M, Lleóart Bellfill R, Pujol Farriols R. Dystonia laríngea aguda por cleboprida que simula reacción alérgica [Acute

- laryngeal dystonia due to clebopride simulating allergic reaction]. *Med Clin (Barc)*. 2007;129(6):238–9.
- [127] Ramsden SC, Pergjika A, Janssen AC, Mudahar S, Fawcett A, Walkup JT, et al. A systematic review of the effectiveness and safety of droperidol for pediatric agitation in acute care settings. *Acad Emerg Med*. 2022;29(12):1466–74.
- [128] Page CB, Parker LE, Rashford SJ, Bosley E, Isoardi KZ, Williamson FE, et al. A prospective before and after study of droperidol for prehospital acute behavioral disturbance. *Prehosp Emerg Care*. 2018;22(6):713–21.
- [129] Page CB, Parker LE, Rashford SJ, Isoardi KZ, Isbister GK. A prospective study of the safety and effectiveness of droperidol in children for pre-hospital acute behavioral disturbance. *Prehosp Emerg Care*. 2019;23(4):519–26.
- [130] Cole JB, Klein LR, Strobel AM, Blanchard SR, Nahum R, Martel ML. The use, safety, and efficacy of olanzapine in a level I pediatric trauma center emergency department over a 10-year period. *Pediatr Emerg Care*. 2020;36(2):70–6.
- [131] Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. *Ann Emerg Med*. 2006;47(1):61–7.
- [132] Park CK, Choi HY, Oh IY, Kim MS. Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients. *J Korean Med Sci*. 2002;17(5):715–7.
- [133] Bak M, Weltens I, Bervoets C, De Fruyt J, Samochowiec J, Fiorillo A, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. *Eur Psychiatry*. 2019;57:78–100.
- [134] Berna F, Timbolschi ID, Diemunsch P, Vidailhet P. Acute dystonia and akathisia following droperidol administration misdiagnosed as psychiatric disorders. *J Anesth*. 2013;27(5):803–4.
- [135] Yamada S, Suzuki T, Oe K, Serada K. [Case of acute dystonia during epidural droperidol infusion to prevent postoperative nausea and vomiting]. *Masui*. 2010;59(2):238–41.
- [136] Walker M, Samii A. Chronic severe dystonia after single exposure to antiemetics. *Am J Emerg Med*. 2006;24(1):125–7.
- [137] Brown ES, Dilsaver SC, Bowers TC, Swann AC. Droperidol in the interim management of severe mania: case reports and literature review. *Clin Neuropharmacol*. 1998;21(5):316–8.
- [138] Arrowsmith J, Gams RA. Dystonia with droperidol therapy. *N Engl J Med*. 1981;305(4):227.
- [139] Duarte A, Teive HAG. Lingual dystonia secondary to medication use: a review of case reports (P12-11.004). *Neurology*. 2023;100(17, Suppl 2).
- [140] Michailidou M, Peck T. Dystonic reaction to cyclizine. *Anaesthesia*. 2004;59(4):413–4.
- [141] Dagg LE, Wrathall DW. Dystonic reactions to cyclizine. *Anaesthesia*. 2003;58(7):724.
- [142] Sewell A, Nixon M. Dystonic reaction to cyclizine. *Anaesthesia*. 2003;58(9):928.
- [143] Peiris RS, Peckler BF. Cimetidine-induced dystonic reaction. *J Emerg Med*. 2001;21(1):27–9.
- [144] Kapur V, Barber KR, Peddireddy R. Ranitidine-induced acute dystonia. *Am J Emerg Med*. 1999;17(3):258–60.
- [145] Wilson LB, Woodward AM, Ferrara JJ. An acute dystonic reaction with long-term use of ranitidine in an intensive care unit patient. *J La State Med Soc*. 1997;149(1):36–8.
- [146] Bucci KK, Haverstick DE, Abercrombie SA. Dystonic-like reaction following cisapride therapy. *J Fam Pract*. 1995;40(1):86–8.
- [147] Davis BJ, Aul EA, Granner MA, Rodnitzky RL. Ranitidine-induced cranial dystonia. *Clin Neuropharmacol*. 1994;17(5):489–91.
- [148] Romisher S, Felter R, Dougherty J. Tagamet-induced acute dystonia. *Ann Emerg Med*. 1987;16(10):1162–4.
- [149] Cascade E, Kalali AH, Weisler RH. Varying uses of anticonvulsant medications. *Psychiatry (Edmont)*. 2008;5(6):31–3.
- [150] Sáenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Antiepileptic drugs and movement disorders. *CNS Drugs*. 2022;36(8):859–76.
- [151] Zhou DJ, Pavuluri S, Snehal I, Schmidt CM, Situ-Kcomt M, Taraschenko O. Movement disorders associated with antiepileptic medications: a systematic review. *Epilepsy Behav*. 2022;131(Pt A):108693.
- [152] Muralidharan A, Rahman J, Banerjee D, Hakim Mohammed AR, Malik BH. Parkinsonism: a rare adverse effect of valproic acid. *Cureus*. 2020;12(6):e8782.
- [153] Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. *J Neurol Sci*. 2022;435:120192.
- [154] Rissardo JP, Caprara ALF, Durante Í. Valproate-associated movement disorder: a literature review. *Prague Med Rep*. 2021;122(3):140–80.
- [155] Zhang CQ, He BM, Hu ML, Sun HB. Risk of valproic acid-related tremor: a systematic review and meta-analysis. *Front Neurol*. 2020;11:576579.
- [156] Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. *Clin Neuropharmacol*. 2020;43(3):66–80.
- [157] Rissardo JP, Fornari Caprara AL. Lamotrigine-associated movement disorder: a literature review. *Neurol India*. 2021;69(6):1524–38.
- [158] Rissardo JP, Caprara ALF. Phenytoin-associated movement disorder: a literature review. *Tzu Chi Med J*. 2022;34(4):409–17.
- [159] Chalhub EG, Devivo DC, Volpe JJ. Phenytoin-induced dystonia and choreoathetosis in two retarded epileptic children. *Neurology*. 1976;26(5):494–8.
- [160] Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. *J Neurol Neurosurg Psychiatr*. 1976;39(12):1210–8.
- [161] Rajkumar D, Manokaran RK, Shubha S, Shruthi TK. Phenytoin induced status dystonicus: a rare manifestation of phenytoin toxicity in a child with autism spectrum disorder. *Indian J Pediatr*. 2021;88(1):85–6.
- [162] Wolańczyk T, Grabowska-Grzyb A. Transient dystonias in three patients treated with tiagabine. *Epilepsia*. 2001;42(7):944–6.
- [163] Ge L, Li A, Wang N, Li P, Xin H, Li W. Pregabalin-associated stuttering and frequent blepharospasm: case report and review. *Daru*. 2020;28(2):815–8.
- [164] Peacock DJSJ, Yoneda JRK, Siever JE, Vis-Dunbar M, Boelman C. Movement disorders secondary to novel antiepileptic medications in pediatric populations: a systematic review and meta-analysis of risk. *J Child Neurol*. 2022;37(6):524–33.
- [165] Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. *Neurol Int*. 2021;13(3):387–401.
- [166] Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. *Ann Pharmacother*. 2015;49(10):1136–52.
- [167] Erden S, Ferahkaya H. Acute dystonia after low-dose sertraline treatment: a case presentation and review of the literature. *J Clin Psychopharmacol*. 2023;43(1):73–4.
- [168] Gupta B, Ahmad J, Kar SK, Shrivastava A. Sertraline induced cervical dystonia in a patient of obsessive compulsive disorder. *Asian J Psychiatr*. 2018;31:77–8.
- [169] Hiremath SB, Desai M. Amitriptyline induced cervical dystonia. *J Sci Soc*. 2016;43(1):38–40.
- [170] Skarmeta NP, Katzmann GC, Valdés C, Gaedechens D, Montini FC. Tardive oromandibular dystonia induced by trazodone: a clinical case and management from the perspective of the dental specialist. *Toxins (Basel)*. 2022;14(10):680.
- [171] Abu-Naser D, Gharaibeh S, Al Meslamani AZ, Alefan Q, Abunaser R. Assessment of extrapyramidal symptoms associated with psychotropics pharmacological treatments, and associated risk factors. *Clin Pract Epidemiol Ment Health*. 2021;17:1–7.
- [172] Mörk S, Selteneich D, Letmaier M, et al. Extrapyramidal reactions following treatment with antidepressants: results of the AMSP multinational drug surveillance programme. *World J Biol Psychiatr*. 2020;21(4):308–16.
- [173] Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. *BMC Psychiatr*. 2020;20(1):308.
- [174] Uvais NA, Sreeraj VS, Sathish Kumar SV. Sertraline induced mandibular dystonia and bruxism. *J Family Med Prim Care*. 2016;5(4):882–4.
- [175] Raveendranathan D, Rao SG. Sertraline induced acute mandibular dystonia. *J Neurosci Rural Pract*. 2015;6(4):586–7.

- [176] Lee Y, Lin PY, Chang YY, Chong MY, Cheng AT. Antidepressant-induced tardive syndrome: a retrospective epidemiological study. *Pharmacopsychiatry*. 2013;46(7):281–5.
- [177] Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyrimal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. *Ann Clin Psychiatry*. 2010;22(3):148–56.
- [178] Caley CF. Extrapyrimal reactions and the selective serotonin-reuptake inhibitors. *Ann Pharmacother*. 1997;31(12):1481–9.
- [179] Vandewalle W, Boon E, Sienaert P. Bewegingsstoornissen door antidepressiva en stemmingsstabilisatoren [Movement disorders due to modern antidepressants and mood stabilizers]. *Tijdschr Psychiatr*. 2015;57(2):132–7.
- [180] Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. *J Clin Psychiatry*. 1996;57(10):449–54.
- [181] Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. *Psychother Psychosom*. 2016;85(5):270–88.
- [182] Gill HS, DeVane CL, Risch SC. Extrapyrimal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. *J Clin Psychopharmacol*. 1997;17(5):377–89.
- [183] Šarac I, Šarac H, Henigsberg N, Borovečki F, Božina N, Pašić H, et al. Craniocervical dystonia induced by oxycodone-escitalopram: possible role of gene polymorphism and drug-drug interactions. *Psychiatr Danub*. 2022;34(3):506–8.
- [184] Doruk N, Dogrul BN. Sertraline induced oromandibular dystonia and galactorrhea: a case report. *Psychiatr Danub*. 2021;33(2):191–2.
- [185] Abdipranoto J, Smith B, d'Abrera JC. Sertraline-induced acute mandibular dystonia. *Aust N Z J Psychiatr*. 2021;55(5):522–3.
- [186] Caffrey D, Sowden G, Arsan C. A possible case of escitalopram-induced tardive dystonia. *Psychosomatics*. 2020;61(2):188–92.
- [187] Kutuk MO, Güler Aksu G, Tufan AE, Celik T. Oromandibular dystonia related to sertraline treatment in a child. *J Child Adolesc Psychopharmacol*. 2019;29(2):164–5.
- [188] Wang LF, Huang JW, Shan SY, Ding JH, Lai JB, Xu Y, et al. Possible sertraline-induced extrapyramidal adverse effects in an adolescent. *Neuropsychiatr Dis Treat*. 2016;12:1127–9.
- [189] Ayaydin H, Bozkurt H. Spasmodic torticollis associated with sertraline in a child and an adolescent. *Turk J Pediatr*. 2015;57(1):109–11.
- [190] Guo MY, Etmnan M, Procyshyn RM, Kim DD, Samii A, Kezouh A, et al. Association of antidepressant use with drug-related extrapyramidal symptoms: a pharmacoepidemiological study. *J Clin Psychopharmacol*. 2018;38(4):349–56.
- [191] Kadota Y, Hori H, Takayama M, Okabe C, Ohara N. Tardive dystonia improved with discontinuation of trazodone in an elderly schizophrenia patient: a case report. *Ann Gen Psychiatry*. 2020;19:23.
- [192] Lin CC, Lin PY, Lee Y, Chang YY, Chen CH. Tardive dystonia and tardive sensory syndrome related to trazodone: a case report. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(6):1609–10.
- [193] Lewis CF, DeQuardo JR, Tandon R. Dystonia associated with trazodone and sertraline. *J Clin Psychopharmacol*. 1997;17(1):64–5.
- [194] Kramer MS, Marcus DJ, DiFerdinando J, Dewey D. Atypical acute dystonia associated with trazodone treatment. *J Clin Psychopharmacol*. 1986;6(2):117–8.
- [195] Rissardo JP, Caprara ALF. Mirtazapine-associated movement disorders: a literature review. *Tzu Chi Med J*. 2020;32(4):318–30.
- [196] Thour A, Marwaha R. Amitriptyline. [Updated 2023 Jul 18]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537225/>. Last Access 6 September 2024.
- [197] Rissardo JP, Caprara ALF. The link between amitriptyline and movement disorders: clinical profile and outcome. *Ann Acad Med Singap*. 2020;49(4):236–51.
- [198] Allsbrook M, Fries BE, Szafara KL, Regal RE. Do SSRI antidepressants increase the risk of extrapyramidal side effects in patients taking antipsychotics? *Medicine* 2016;41(2):115–9.
- [199] Hayashi Y, Ohyagi Y, Inoue I, Arakawa K, Taniwaki T, Nakagawa M, et al. [A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent]. *Rinsho Shinkeigaku*. 2000;40(4):367–71.
- [200] Gardos G. Undiagnosed dystonic reaction secondary to amoxapine. *Psychosomatics*. 1984;25(1):66, 69.
- [201] Hunt-Fugate AK, Zander J, Lesar TS. Adverse reactions due to dopamine blockade by amoxapine. A case report and review of the literature. *Pharmacotherapy*. 1984;4(1):35–9.
- [202] Jarecke CR, Reid PJ. Acute dystonic reaction induced by a monoamine oxidase inhibitor. *J Clin Psychopharmacol*. 1990;10(2):144–5.
- [203] Pande AC, Max P. A dystonic reaction occurring during treatment with tranlycypromine. *J Clin Psychopharmacol*. 1989;9(3):229–30.
- [204] El Zahran T, Al Hassan S, Khalifeh M, Aboukhater D, Hammoud L, Al Hariri M, et al. Melitraxen and flupentixol (deanxit) use disorder in Lebanon. *Heliyon*. 2023;9(5):e15847.
- [205] Qin L, Qin J, Yang Q, Lv X, Huang L. Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2019;98(2):e14064.
- [206] Kao Y, Shiah I, Lee W, Kuo S, Huang C, Ku Y. Deanxit-associated tardive dyskinesia and tardive akathisia in a depressed patient. *Acta Neuropsychiatrica*. 2010; 22(1):47–8.
- [207] Bhaumik S. India's health ministry bans pioglitazone, metamizole, and flupentixol-melitracen. *BMJ*. 2013;347:f4366.
- [208] Rissardo JP, Caprara ALF, Durante Í, Rauber A. Lithium-associated movement disorder: a literature review. *Brain Circ*. 2022;8(2):76–86.
- [209] Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. *Am J Psychiatry*. 1988;145(11):1455–6.
- [210] Aggarwal R, Garg D, Dhamija RK. Lithium-induced lingual dystonia. *Ann Indian Acad Neurol*. 2020;23(3):383–4.
- [211] Chakrabarti S, Chand PK. Lithium - induced tardive dystonia. *Neurol India*. 2002;50(4):473–5.
- [212] Pagliaro A, Mattio B, Paulson N, Fromm C, Vidal J. Unprovoked dystonic reaction in a child taking long-term methylphenidate. *J Pharm Pract*. 2022;35(5):796–9.
- [213] Uzun ME, Korkmaz MF, Ekici A, Kaymaz N. Methylphenidate induced acute dystonic reaction. *Indian J Pediatr*. 2018;85(7):577.
- [214] Mohamoud M, Chen Q, Croteau D, Cheng C, Burkhardt K, Volpe DA, et al. Acute hyperkinetic movement disorders as a multifactorial pharmacodynamic drug interaction between methylphenidate and risperidone in children and adolescents. *J Clin Psychopharmacol*. 2022;42(3):238–46.
- [215] Millichap JG, Yee MM. Dystonia with MPH/risperidone combined therapy for ADHD. *Pediatr Neurol Briefs*. 2016;30(1):7.
- [216] LeRiger M, Williams J, Duncan-Wiebe G, Shukry M. Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia. *Paediatr Anaesth*. 2017; 27(8):863–4.
- [217] Grau-López L, Daigne C, Mercado N, Casas M, Roncero C. Dystonia in methylphenidate withdrawal: a case report. *J Addict Med*. 2017;11(2):154–6.
- [218] Pellicchia MT, Esposito M, Cozzolino A, Squillante M, Penza P, Barone P. Drug induced oromandibular dystonia: a case related to prolonged use of cetirizine. *Parkinsonism Relat Disord*. 2014;20(5):566–7.
- [219] Bawany FI, Khan MS, Naeem M, Shoaib AB. Cetirizine: an antihistamine associated with dystonia and oculogyric crises. *J Pak Med Assoc*. 2013; 63(9):1216.
- [220] Romo CA, Joshi KG, Waters BM. Involuntary movements associated with cetirizine use. *Am J Psychiatry*. 2011;168(8):855.
- [221] Esen I, Demirpence S, Yis U, Kurul S. Cetirizine-induced dystonic reaction in a 6-year-old boy. *Pediatr Emerg Care*. 2008;24(9):627–8.
- [222] Fraunfelder FW, Fraunfelder FT. Oculogyric crisis in patients taking cetirizine. *Am J Ophthalmol*. 2004;137(2):355–7.
- [223] Rajput A, Baerg K. Cetirizine-induced dystonic movements. *Neurology*. 2006;66(1):143–4.
- [224] Sicari V, Zabbo CP. Diphenhydramine. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024 Jan.

- [225] Serrano M, Sanz-Cuesta M, Villaronga M, Hayek LF, Perez-Dueñas B. Cloperastine-based cough syrup and acute dystonic reactions. *Dev Med Child Neurol.* 2012;54(3):287.
- [226] Etzel JV. Diphenhydramine-induced acute dystonia. *Pharmacotherapy.* 1994;14(4):492–6.
- [227] Roila F, Donati D, Basurto C, Del Favero A. Diphenhydramine and acute dystonia. *Ann Intern Med.* 1989;111(1):92–3.
- [228] Santora J, Rozek S, Samie MR. Diphenhydramine-induced dystonia. *Clin Pharm.* 1989;8(7):471.
- [229] Lavenstein BL, Cantor FK. Acute dystonia. An unusual reaction to diphenhydramine. *JAMA.* 1976;236(3):291.
- [230] Khater DA, Daou R, Dailaty AA, Helou M. Diphenhydramine induced acute dystonia: a case report. *Pan Afr Med J.* 2022;42:289.
- [231] Joseph MM, King WD. Dystonic reaction following recommended use of a cold syrup. *Ann Emerg Med.* 1995;26(6):749–51.
- [232] Gaudins A, Fern RP. Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup. *J Toxicol Clin Toxicol.* 1996;34(3):351–2.
- [233] Wijerathne T. Prolonged lower limb dystonia and dysphonia following general anaesthesia in a patient on Hydroxyzine. *J Anesth Crit Care Open Access.* 2024;16(4):102–4.
- [234] Gunduz S, Karacayir N, Ozkan M. Hydroxyzine induced dystonia. *Austin Pediatr.* 2016;3(1):1026.
- [235] Linazasoro G, Garmendia MT, Lizaso X. Acute dystonia in a young schizophrenic patient associated with ingestion of a cloperastine containing cough syrup. *Parkinsonism Relat Disord.* 2000;6(1):57–8.
- [236] Jhang KM, Huang JY, Nfor ON, et al. Flunarizine related movement disorders: a nationwide population-based study. *Sci Rep.* 2019;9(1):1705.
- [237] Jhang KM, Huang JY, Nfor ON, Tung YC, Ku WY, Lee CT, Liaw YP. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. *Eur J Clin Pharmacol.* 2017;73(7):911–6.
- [238] Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. *Arq Neuropsiquiatr.* 2004;62(3B):784–8.
- [239] Vadlamudi L, Wijidicks EF. Multifocal myoclonus due to verapamil overdose. *Neurology.* 2002;58(6):984.
- [240] Pina MA, Ara JR, Remírez A, Castiella J. Verapamil and acute dystonia. *J Clin Pharm Ther.* 1998;23(1):79–80.
- [241] Hicks CB, Abraham K. Verapamil and myoclonic dystonia. *Ann Intern Med.* 1985;103(1):154.
- [242] Singh I. Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime. *Br J Psychiatry.* 1987;150:127–8.
- [243] Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. *Pediatr Emerg Care.* 2012;28(1):55–6.
- [244] Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. *Mov Disord.* 1992;7(1):62–3.
- [245] Nachane HB, Nayak AS. Acute dystonic reaction due to a combination of chloroquine and doxycycline in an emergency psychiatry setting. *Indian J Psychiatry.* 2020;62(6):736–8.
- [246] Busari OA, Fadare J, Agboola S, Gabriel O, Elegbede O, Oladosu Y. Chloroquine-induced acute dystonic reactions after a standard therapeutic dose for uncomplicated malaria. *Sultan Qaboos Univ Med J.* 2013;13(3):E476–8.
- [247] Achumba JI, Ette EI, Thomas WO, Essien EE. Chloroquine-induced acute dystonic reactions in the presence of metronidazole. *Drug Intell Clin Pharm.* 1988;22(4):308–10.
- [248] Adjei GO, Goka BQ, Rodrigues OP, Hoegberg LC, Alifrangis M, Kurtzhals J. Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose. *Ghana Med J.* 2009;43(3):135–8.
- [249] Akindele MO, Odejide AO. Amodiaquine-induced involuntary movements. *Br Med J.* 1976;2(6029):214–5.
- [250] Amponsah EK, Sodnom-Ish B, Anyetei-Anum AS, Frimpong P, Kim SM. Adverse reaction to Coartem (artemether/lumefantrine) resulting in oculogyric crisis. *Maxillofac Plast Reconstr Surg.* 2021;43(1):13.
- [251] Omrani A, Rohani M, Hosseinpour S, Tavasoli AR. Persistent dystonia and basal ganglia involvement following metronidazole induced encephalopathy. *Neurol Sci.* 2020;41(4):957–9.
- [252] Mondet L, Radoubé F, Gras V, Masmoudi K. Cefixime-induced oromandibular dystonia in an adult: a case report. *Curr Drug Saf.* 2017, Mar 9. <https://doi.org/10.2174/1574886312666170310095320>.
- [253] Sharma DD, Aggarwal A, Sharma RC, Kumar R. A probable association of acute dystonia with gemifloxacin administration. *Indian J Med Sci.* 2009;63(12):557–560.
- [254] Ersunan G, Bilir O, Kalkan A, Yavasi O, Kayayurt K. Acute dystonic reaction associated with cefuroxime Axetil in a child. *J Clin Case Rep.* 2015;5(1):486.
- [255] Shihabudheen P, Uvais NA. Multifocal dystonia induced by levofloxacin. *Asian J Pharm Pharmacol.* 2018;4(1): 87–9.
- [256] Lizarraga KJ, Lopez MR, Singer C. Reversible craniocervical dystonia associated with levofloxacin. *Clin Mov Disord.* 2015;2:10.
- [257] Rissardo JP, Caprara ALF. Fluoroquinolone-associated movement disorder: a literature review. *Medicines (Basel).* 2023;10(6):33.
- [258] Yildiz MÇ, Arslan M, Gökçenoglu Y, Çalıskan AM, Çalıskan S, Eren I. Dystonia as an unexpected interaction of ciprofloxacin and clozapine: a case report. *Psychi Clin Psychopharmacol.* 2019; 29:181.
- [259] Philips CA, Augustine P. Levofloxacin associated fatal oro-facio-brachial dystonia in cirrhosis. *OGH Reports.* 2018;10:12–14.
- [260] Ridout KK, Ridout SJ, Pirnie LF, Puttichanda SP. Sudden-onset dystonia in a patient taking asenapine: interaction between ciprofloxacin and asenapine metabolism. *Am J Psychiatry.* 2015;172(11):1162–3.
- [261] Azar S, Ramjani A, Van Gerpen JA. Ciprofloxacin-induced chorea. *Mov Disord.* 2005;20(4):513–4.
- [262] Tomic S, Rotim T, Hlavati M, Kramaric RP, Zubonja TM. Acute dystonic reaction associated with cefalexine. *Neurol Sci.* 2015;36(8):1493–4.
- [263] Benazzi F. Spiramycin-associated acute dystonia during neuroleptic treatment. *Can J Psychiatry.* 1997;42(6):665–6.
- [264] Brady W, Hall K. Erythromycin-related dystonic reaction. *Am J Emerg Med.* 1992;10(6):616.
- [265] Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to β -lactam antibiotics: a literature review. *Drug Saf.* 2017;40(12): 1171–98.
- [266] Dubow JS, Panush SR, Rezak M, Leikin J. Acute dystonic reaction associated with foscarnet administration. *Am J Ther.* 2008;15(2):184–6.
- [267] Song X, Hu Z, Zhang H. Acute dystonia induced by lamivudine. *Clin Neuropharmacol.* 2005;28(4):193–4.
- [268] Patel M, Park BL. Acute dystonic reaction in the upper extremity following anesthesia. *Cureus.* 2022;14(11):e31166.
- [269] Jitprapaikulsan J, Srivanthapoom P. Acute dystonic reaction following general anesthetic agent use. *Tremor Other Hyperkinet Mov (N Y).* 2017; 7:514.
- [270] Iselin-Chaves IA, Gröttsch H, Besson M, Burkhard PR, Savoldelli GL. Naloxone-responsive acute dystonia and parkinsonism following general anaesthesia. *Anaesthesia.* 2009;64(12):1359–62.
- [271] Burstein AH, Fullerton T. Oculogyric crisis possibly related to pentazocine. *Ann Pharmacother.* 1993;27(7-8):874–6.
- [272] Schramm BM, Orser BA. Dystonic reaction to propofol attenuated by benzotropine (cogentin). *Anesth Analg.* 2002;94(5):1237–40.
- [273] Cosgrove P, Krauss BS, Cravero JP, Flegler EW. Predictors of laryngospasm during 276,832 episodes of pediatric procedural sedation. *Ann Emerg Med.* 2022;80(6):485–96.
- [274] Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH; Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. *Anesth Analg.* 2009;108(3):795–804.
- [275] Bellolio MF, Puls HA, Anderson JL, Gilani WI, Murad MH, Barrionuevo P, et al. Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis. *BMJ Open.* 2016;6(6):e011384.
- [276] Bellolio MF, Gilani WI, Barrionuevo P, Murad MH, Erwin PJ, Anderson JR, et al. Incidence of adverse events in adults undergoing procedural sedation in the emergency department: a systematic review and meta-analysis. *Acad Emerg Med.* 2016;23(2):119–34.

- [277] Lamond DW. Review article: safety profile of propofol for paediatric procedural sedation in the emergency department. *Emerg Med Australas*. 2010;22(4):265–86.
- [278] Hayes JA, Aljuhani T, De Oliveira K, Johnston BC. Safety and efficacy of the combination of propofol and ketamine for procedural sedation/anesthesia in the pediatric population: a systematic review and meta-analysis. *Anesth Analg*. 2021;132(4):979–92.
- [279] Walder B, Tramèr MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. *Neurology*. 2002;58(9):1327–32.
- [280] Bragonier R, Bartle D, Langton-Hewer S. Acute dystonia in a 14-yr-old following propofol and fentanyl anaesthesia. *Br J Anaesth*. 2000;84(6):828–9.
- [281] Bernard JM, Le Roux D, Péréon Y. Acute dystonia during sevoflurane induction. *Anesthesiology*. 1999;90(4):1215–6.
- [282] Boonmak P, Boonmak S, Pattanittum P. High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia. *Cochrane Database Syst Rev*. 2016;2016(6):CD006837.
- [283] Singh PM, Trikha A, Sinha R, Rewari V, Ramachandran R, Borle A. Sevoflurane induction procedure: cost comparison between fixed 8% versus incremental techniques in pediatric patients. *AANA J*. 2014;82(1):32–7.
- [284] Martín-Larrauri R, Gilsanz F, Rodrigo J, Vila P, Ledesma M, Casimiro C. Conventional stepwise vs. vital capacity rapid inhalation induction at two concentrations of sevoflurane. *Eur J Anaesthesiol*. 2004;21(4):265–71.
- [285] Epstein RH, Stein AL, Marr AT, Lessin JB. High concentration versus incremental induction of anesthesia with sevoflurane in children: a comparison of induction times, vital signs, and complications. *J Clin Anesth*. 1998;10(1):41–5.
- [286] Erb TO, von Ungern-Sternberg BS, Moll J, Frei FJ. Impact of high concentrations of sevoflurane on laryngeal reflex responses. *Paediatr Anaesth*. 2017;27(3):282–9.
- [287] Li C, Zhu Y. Impact of sevoflurane and propofol on perioperative respiratory adverse events in pediatrics: a systematic review and meta-analysis. *J Perianesth Nurs*. 2024;S1089-9472(24)00097-2.
- [288] Sharawat IK, Suthar R. Drug induced acute dystonic reaction. *Indian Pediatr*. 2018;55(11):1003.
- [289] Mahadevappa M, Attri LK, Chalasani SH, Syed J. Dextromethorphan induced dystonia: a rare case report. *Hosp Pharm*. 2023;58(4):353–6.
- [290] Paul IM, Reynolds KM, Kauffman RE, et al. Adverse events associated with pediatric exposures to dextromethorphan. *Clin Toxicol (Phila)*. 2017;55(1):25–32.
- [291] Bayram E, Karakaya P, Topcu Y, Yis U, Hiz S. Acute cervical dystonia after the first dose of butamirate citrate. *Pediatr Emerg Care*. 2013;29(1):80–1.
- [292] Polizzi A, Incorpora G, Ruggieri M. Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl. *Eur J Paediatr Neurol*. 2001;5(4):167–8.
- [293] Warden CR, Diekema DS, Robertson WO. Dystonic reaction associated with dextromethorphan ingestion in a toddler. *Pediatr Emerg Care*. 1997;13(3):214–5.
- [294] Yılmaz-Topa Ö, Tuygun N, Akça H, Polat E, Karacan CD. Cetirizine and alendazole induced dystonia in a child. *Turk J Pediatr*. 2015;57(4):407–8.
- [295] Incecik F, Hergüner MO, Özcan K, Altunbaşak S. Albendazole-induced dystonic reaction: a case report. *Turk J Pediatr*. 2011;53(6):709–10.
- [296] De Riu G, Sanna MP, De Riu PL. An elderly female patient with tardive oromandibular dystonia after prolonged use of the histamine analog betahistine. *J Clin Neurosci*. 2010;17(10):1330–1.
- [297] Mascías J, Pérez OS, Chaverri D, Mora JS. Dystonia aguda secundaria a tratamiento con betahistina [Acute dystonia secondary to treatment with betahistine]. *Neurología*. 2000;15(9):417.
- [298] López-Blanco R, Guerrero-Molina MP, González-de la Aleja J, Ruiz-Morales J. Acute Pisa syndrome secondary to betahistine treatment in a patient with mild cognitive impairment. *Neurología (Engl Ed)*. 2018;33(3):204–5.
- [299] Cengiz A, Aybay MN, Sarıcı SF, Öner V, Arslan FZ, Cengiz A. Capecitabine-related neurotoxicity presenting as oromandibular dystonia. *J Oncol Pract*. 2018;14(3):202–4.
- [300] van Pelt-Sprangers MJ, Geijteman EC, Alsmas J, Boere IA, Mathijssen RH, Schuit SC. Oromandibular dystonia: a serious side effect of capecitabine. *BMC Cancer*. 2015;15:115.
- [301] Ngeow JY, Prakash KM, Chowbay B, Quek ST, Choo SP. Capecitabine-induced oromandibular dystonia: a case report and literature review. *Acta Oncol*. 2008;47(6):1161–5.
- [302] Janik P, Figura M. Tetrabenazine-induced oculogyric crisis – a rare complication in the treatment of Gilles de la Tourette syndrome. *Neuropsychiatr Dis Treat*. 2016;12:497–9.
- [303] Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. *Ann Neurol*. 1985;17(2):200–2.
- [304] Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. *Neurology*. 1997;48(2):358–62.
- [305] Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. *Mov Disord*. 2007;22(2):193–7.
- [306] Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the adverse drug reaction reporting system. *J Am Acad Dermatol*. 1988;18(3):543–52.
- [307] Miklavčič P, Avčin S, Jazbec J, Vipotnik Vesnaver T, Todorova B, Trošt M, et al. Cyclosporine A induced dystonia-parkinsonism. *J Neurol Sci*. 2017;375:68–70.
- [308] Taque S, Peudener S, Gie S, Rambeau M, Gandemer V, Bridoux L, et al. Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. *Pediatr Nephrol*. 2004;19(3):276–80.
- [309] Liu Y, Yan C, Zhao Y, Deng S, Zu J. The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database. *Front Pediatr*. 2025;12:1487441.
- [310] Wasilczuk AZ, Rinehart C, Aggarwal A, Stone ME, Mashour GA, Avidan MS, et al. Hormonal basis of sex differences in anesthetic sensitivity. *Proc Natl Acad Sci USA*. 2024;121(3):e2312913120.
- [311] Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y. Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. *Intern Med*. 2014;53(9):1007–10.
- [312] Pavlis CJ, Kutscher EC, Carnahan RM, Kennedy WK, Van Gerpen S, Schlenker E. Rivastigmine-induced dystonia. *Am J Health Syst Pharm*. 2007;64(23):2468–70.
- [313] Dhikav V, Anand KS. Acute dystonic reaction with rivastigmine. *Int Psychogeriatr*. 2013;25(8):1385–6.
- [314] Mukku SSR, Achary U, Sivakumar PT, Varghese M. Recurrent truncal dystonia (Pisa syndrome) due to donepezil – a case report. *Asian J Psychiatr*. 2018;35:47–9.
- [315] Yagi Y, Watanabe Y, Yokote H, Amino T, Kamata T. Cervical dystonia in an Alzheimer's disease patient treated with donepezil. *Acta Neurol Belg*. 2013;113(3):363–4.
- [316] Cossu G, Melis M, Melis G, Maccioni E, Putzu V, Catta O, et al. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. *Mov Disord*. 2004;19(10):1243–4.
- [317] Singh R, Sadiq NM. Cholinesterase inhibitors. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025, Jan. <https://www.ncbi.nlm.nih.gov/books/NBK544336/>.
- [318] Zannas AS, Okuno Y, Doraiswamy PM. Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. *Pharmacotherapy*. 2014;34(3):272–8.
- [319] Komur M, Arslankoylu AE, Okuyaz C. Midazolam-induced acute dystonia reversed by diazepam. *J Anaesthesiol Clin Pharmacol*. 2012;28(3):368–70.
- [320] Stolarek IH, Ford MJ. Acute dystonia induced by midazolam and abolished by flumazenil. *BMJ*. 1990;300(6724):614.
- [321] Pérez Trullen JM, Modrego Pardo PJ, Vázquez André M, López Lozano JJ. Bromazepam-induced dystonia. *Biomed Pharmacother*. 1992;46(8):375–6.
- [322] Hooker EA, Danzl DF. Acute dystonic reaction due to diazepam. *J Emerg Med*. 1988;6(6):491–3.
- [323] Wakakura M, Yamagami A, Iwasa M. Blepharospasm in Japan: a clinical observational study from a large referral hospital in Tokyo. *Neuroophthalmology*. 2018;42(5):275–83.

- [324] Wakakura M, Tsubouchi T, Inouye J. Etizolam and benzodiazepine induced blepharospasm. *J Neurol Neurosurg Psychiatr*. 2004;75(3):506–7.
- [325] Emorinken A, Agbadaola OR. Metoclopramide-induced acute dystonia misdiagnosed as an epileptic seizure in a lupus patient. *J Epilepsy Res*. 2021;11(2):156–8.
- [326] Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. *J Psychopharmacol*. 2012;26(5 Suppl):15–26.
- [327] Pandey S, Pitakpatapee Y, Saengphatrachai W, Chouksey A, Tripathi M, Srivanitchapoom P. Drug-induced movement disorders. *Semin Neurol*. 2023;43(1):35–47.
- [328] Jiwanmall SA, Gopalakrishnan R, Kuruvilla A. Tardive laryngeal dystonia with risperidone – a case report. *Indian J Psychiatr*. 2021;63(3):306–7.
- [329] Ganesh M, Jabbar U, Iskander FH. Acute laryngeal dystonia with novel antipsychotics: a case report and review of literature. *J Clin Psychopharmacol*. 2015;35(5):613–5.
- [330] Matsuda N, Hashimoto N, Kusumi I, Ito K, Koyama T. Tardive laryngeal dystonia associated with aripiprazole monotherapy. *J Clin Psychopharmacol*. 2012;32(2):297–8.
- [331] Miodownik C, Lerner V, Witztum E. Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. *Isr J Psychiatry Relat Sci*. 2011;48(3):195–200.
- [332] Tsai CS, Lee Y, Chang YY, Lin PY. Ziprasidone-induced tardive laryngeal dystonia: a case report. *Gen Hosp Psychiatry*. 2008;30(3):277–9.
- [333] Peek DF. A patient with haloperidol induced laryngeal dystonia. *Acta Anaesthesiol Belg*. 2008;59(2):103–5.
- [334] Norton J. Laryngeal dystonia in psychiatry. *Can J Psychiatry*. 2001;46(5):453.
- [335] Salim B, Rashid S, Ali MA, Raza A, Khan FA. Effect of pharmacological agents administered for attenuating the extubation response on the quality of extubation: a systematic review. *Cureus*. 2019;11(12):e6427.
- [336] de Oliveira GS Jr, Girao W, Fitzgerald PC, McCarthy RJ. The effect of sevoflurane versus desflurane on the incidence of upper respiratory morbidity in patients undergoing general anesthesia with a Laryngeal Mask Airway: a meta-analysis of randomized controlled trials. *J Clin Anesth*. 2013;25(6):452–8.
- [337] Yagmur F, Ulusoy HB, Buyukoglan H, Kaya MG. Acute respiratory distress due to antipsychotic drugs. *Pharmacopsychiatr*. 2010;43(3):118–9.
- [338] Modestin J, Krapf R, Böker W. A fatality during haloperidol treatment: mechanism of sudden death. *Am J Psychiatr*. 1981;138(12):1616–7.
- [339] Balint B, Mencacci NE, Valente EM, Pisani A, Rothwell J, Jankovic J, et al. Dystonia. *Nat Rev Dis Primers*. 2018;4(1):25.
- [340] Sáenz-Farret M, Micheli F. Anticholinergics in the treatment of dystonia. In: Dressler D, Altenmüller E, Krauss J. (eds) *Treatment of dystonia*. 2018; pp. 268–71.
- [341] Catthoor K, De Hert M, Detraux J. Dystonie door medicatiegebruik. Fonds Secundaire Dystonie, Koning Boudewijnstichting; 2023. <https://kbs-frb.be/nl/dystonie-door-medicatiegebruik#:~:text=Dystonie%20door%20medicatiegebruik%20kan%20een,laat%20wordt%20gediagnosticeerd%20en%20behandeld>.
- [342] Wager E, Wiffen PJ. Ethical issues in preparing and publishing systematic reviews. *J Evid Based Med*. 2011;4(2):130–4.